ALS Today is an independent interactive news magazine featuring the latest research advances and potential therapies for ALS/MND. Published by ALS TDI, ALS Today informs clinicians, research scientists, patients and care providers about global efforts to end ALS. Find us online www.als.net/ALSToday. Follow us on Twitter @ALSToday.
TMS, a headstart for PALS?
Steve Vucic PhD of Neuroscience Research Australia talks about transcranial magnetic stimulation (TMS), an emerging test that may help clinicians identify people with ALS before the first symptoms of disease. Learn more: http://blogs.als.net/post/2013/06/19/TMS-a-headstart-for-PALS.aspx
Paul Gordon MD of the Indian Health Service (HIS) talks about his latest results which suggest that ALS might be less common in Native Americans. His studies may one day help identify triggers of ALS and potential ways to fight the disease.
DPS Point Blank
Kirsten Gruis MD of the State University of New York talks about the NeuRX DPS, a device that aims to help people with ALS breathe better and live longer by electrically conditioning the diaphragm. Learn more: http://blogs.als.net/post/2013/05/07/The-DPS-Point-Blank.aspx
A go for anti-Nogo-A
Pierre-Francois Pradat MD PhD of the Assistance Publique - Hôpitaux de Paris in France talks about GSK's potential ALS medicine ozanezumab, now at phase II. Learn more: http://blogs.als.net/post/2013/04/09/A-Go-For-anti-NOGO-A.aspx
Gilenya, giving ALS the fingo?
Steve Perrin PhD, CEO and CSO of ALS TDI, talks Gilenya, other emerging immunomodulators and their potential to treat ALS going forward. Read more: http://blogs.als.net/post/2013/02/12/Gilenya-giving-ALS-the-fingo.aspx
Mexiletine - channeling ALS?
Michael Weiss MD, Director of the Neuromuscular Diseases Division of the University of Washington School of Medicine, discusses an upcoming phase II clinical trial that puts mexiletine to the test in ALS, a potential early treatment of the disease. Read more: http://blogs.als.net/post/2013/02/05/Mexiletine-channeling-ALS.aspx